CN103596926B - 作为raf激酶抑制剂的稠合三环化合物 - Google Patents

作为raf激酶抑制剂的稠合三环化合物 Download PDF

Info

Publication number
CN103596926B
CN103596926B CN201180069798.XA CN201180069798A CN103596926B CN 103596926 B CN103596926 B CN 103596926B CN 201180069798 A CN201180069798 A CN 201180069798A CN 103596926 B CN103596926 B CN 103596926B
Authority
CN
China
Prior art keywords
compound
ring
alkyl
hydrogen
base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180069798.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN103596926A (zh
Inventor
周昌友
王韶辉
张国良
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baiji Shenzhou Suzhou Biotechnology Co ltd
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Priority to CN201510883345.0A priority Critical patent/CN105348299B/zh
Publication of CN103596926A publication Critical patent/CN103596926A/zh
Application granted granted Critical
Publication of CN103596926B publication Critical patent/CN103596926B/zh
Priority to HK16109391.8A priority patent/HK1221222B/xx
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/02—Ergot alkaloids of the cyclic peptide type

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN201180069798.XA 2011-12-31 2011-12-31 作为raf激酶抑制剂的稠合三环化合物 Active CN103596926B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201510883345.0A CN105348299B (zh) 2011-12-31 2011-12-31 作为raf激酶抑制剂的稠合三环化合物
HK16109391.8A HK1221222B (en) 2016-08-05 Fused tricyclic compounds as raf kinase inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2011/085146 WO2013097224A1 (en) 2011-12-31 2011-12-31 Fused tricyclic compounds as raf kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510883345.0A Division CN105348299B (zh) 2011-12-31 2011-12-31 作为raf激酶抑制剂的稠合三环化合物

Publications (2)

Publication Number Publication Date
CN103596926A CN103596926A (zh) 2014-02-19
CN103596926B true CN103596926B (zh) 2015-11-25

Family

ID=48696279

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180069798.XA Active CN103596926B (zh) 2011-12-31 2011-12-31 作为raf激酶抑制剂的稠合三环化合物

Country Status (28)

Country Link
US (3) US9273046B2 (cg-RX-API-DMAC7.html)
EP (2) EP3124472B1 (cg-RX-API-DMAC7.html)
JP (1) JP5868521B2 (cg-RX-API-DMAC7.html)
KR (1) KR101713391B1 (cg-RX-API-DMAC7.html)
CN (1) CN103596926B (cg-RX-API-DMAC7.html)
AU (1) AU2011384857B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014013108B1 (cg-RX-API-DMAC7.html)
CA (1) CA2856347C (cg-RX-API-DMAC7.html)
CY (1) CY1118226T1 (cg-RX-API-DMAC7.html)
DK (1) DK2797888T3 (cg-RX-API-DMAC7.html)
EA (1) EA025597B1 (cg-RX-API-DMAC7.html)
ES (1) ES2588775T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20160641T1 (cg-RX-API-DMAC7.html)
HU (1) HUE029656T2 (cg-RX-API-DMAC7.html)
IL (1) IL233364A (cg-RX-API-DMAC7.html)
IN (1) IN2014DN06166A (cg-RX-API-DMAC7.html)
LT (1) LT2797888T (cg-RX-API-DMAC7.html)
ME (1) ME02529B (cg-RX-API-DMAC7.html)
MX (1) MX352617B (cg-RX-API-DMAC7.html)
NZ (1) NZ624068A (cg-RX-API-DMAC7.html)
PL (1) PL2797888T3 (cg-RX-API-DMAC7.html)
PT (1) PT2797888T (cg-RX-API-DMAC7.html)
RS (1) RS55196B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201401725SA (cg-RX-API-DMAC7.html)
SI (1) SI2797888T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201600302B (cg-RX-API-DMAC7.html)
WO (1) WO2013097224A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201405555B (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103596926B (zh) 2011-12-31 2015-11-25 百济神州有限公司 作为raf激酶抑制剂的稠合三环化合物
US9670203B2 (en) * 2013-06-28 2017-06-06 Beigene, Ltd. Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors
WO2014206344A1 (en) 2013-06-28 2014-12-31 Beigene, Ltd. Fused tricyclic amide compounds as multiple kinase inhibitors
WO2015089809A1 (en) * 2013-12-19 2015-06-25 Merck Sharp & Dohme Corp. Antidiabetic substituted heteroaryl compounds
WO2015176267A1 (en) * 2014-05-22 2015-11-26 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
GB201416186D0 (en) 2014-09-12 2014-10-29 Redx Pharma Ltd Compounds
TWI876835B (zh) * 2015-04-15 2025-03-11 英屬開曼群島商百濟神州有限公司 B-raf激酶抑制劑的馬來酸鹽、其結晶形式及用途
JP6175519B2 (ja) * 2016-01-04 2017-08-09 ベイジーン リミテッド Ｒａｆキナーゼ阻害剤としての縮合三環式化合物
WO2018007885A1 (en) * 2016-07-05 2018-01-11 Beigene, Ltd. COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER
BR112019011200B1 (pt) 2016-12-01 2021-12-28 Arvinas Operations, Inc Derivados de tetrahidronaftaleno e tetrahidroisoquinolina como degradadores do receptor de estrogênio
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
CA3047784A1 (en) * 2016-12-23 2018-06-28 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
CN115974840A (zh) 2017-01-31 2023-04-18 阿尔维纳斯运营股份有限公司 人小脑蛋白配体和包含其的双官能化合物
EP3849536A4 (en) 2018-09-10 2022-06-29 Mirati Therapeutics, Inc. Combination therapies
CN111184693B (zh) * 2019-05-29 2023-07-21 百济神州(苏州)生物科技有限公司 一种raf激酶抑制剂制剂及其制备方法
MX2022002415A (es) 2019-08-26 2022-03-22 Arvinas Operations Inc Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos.
CN115175901B (zh) 2019-12-19 2024-03-22 阿尔维纳斯运营股份有限公司 用于雄激素受体的靶向降解的化合物和方法
AU2021314955A1 (en) 2020-07-28 2023-03-30 Jazz Pharmaceuticals Ireland Limited Fused bicyclic Raf inhibitors and methods for use thereof
US12180193B2 (en) 2020-08-28 2024-12-31 Arvinas Operations, Inc. Accelerating fibrosarcoma protein degrading compounds and associated methods of use
AR123492A1 (es) 2020-09-14 2022-12-07 Arvinas Operations Inc Formas cristalinas y amorfas de un compuesto para la degradación dirigida del receptor de estrógeno
JP2024504285A (ja) * 2020-12-29 2024-01-31 ティーエックスイノ バイオサイエンス インコーポレイテッド エクトヌクレオチドピロホスファターゼ－ホスホジエステラーゼの阻害活性を有する新規のナフチリジノン誘導体及びこれらの用途
US20240368109A1 (en) * 2021-09-21 2024-11-07 Merck Sharp & Dohme Llc Allosteric modulators of nicotinic acetylcholine receptors
WO2023212071A1 (en) * 2022-04-26 2023-11-02 Beigene Switzerland Gmbh Combination and the use thereof
WO2023209611A1 (en) 2022-04-26 2023-11-02 Beigene Switzerland Gmbh Methods of treating cancer with a b-raf inhibitor, in particular lifirafenib
WO2024054591A1 (en) 2022-09-07 2024-03-14 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007136572A2 (en) * 2006-05-15 2007-11-29 Merck & Co., Inc. Antidiabetic bicyclic compounds
CN101365682A (zh) * 2005-12-08 2009-02-11 千禧药品公司 具有激酶抑制活性的双环化合物
US20100197924A1 (en) * 2008-12-22 2010-08-05 Millennium Pharmaceuticals, Inc. Preparation of aminotetralin compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003068773A1 (en) 2002-02-12 2003-08-21 Glaxo Group Limited Pyrazolopyridine derivatives
PL1696920T3 (pl) 2003-12-19 2015-03-31 Plexxikon Inc Związki i sposoby opracowywania modulatorów Ret
WO2006065703A1 (en) 2004-12-13 2006-06-22 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
JP2008525355A (ja) 2004-12-23 2008-07-17 エフ．ホフマン−ラ ロシュ アーゲー ベンズアミド誘導体、これらの製造及び医薬剤としての使用。
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
EP1885723A2 (en) 2005-05-17 2008-02-13 Plexxikon, Inc. Pyrrolo[2,3-b]pyridine derivatives as protein kinase inhibitors
CA2609299A1 (en) 2005-05-20 2006-11-23 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
BRPI0611863B1 (pt) 2005-06-22 2021-11-23 Plexxikon, Inc Composto, bem como composição e kit compreendendo o mesmo, composto intermediário na preparação do mesmo, método para tratamento e uso do mesmo
US20070049603A1 (en) 2005-09-01 2007-03-01 Greg Miknis Raf inhibitor compounds and methods of use thereof
ATE530540T1 (de) * 2006-08-23 2011-11-15 Pfizer Prod Inc Pyrimidonverbindungen als gsk-3-inhibitoren
MX2009002010A (es) 2006-09-06 2009-03-05 Hoffmann La Roche Derivados de heteroarilo como inhibidores de la proteina cinasa.
JP2010502706A (ja) * 2006-09-07 2010-01-28 ミレニアム・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害活性を有するフェネチルアミド誘導体
PE20081581A1 (es) 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
WO2008079909A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
BRPI0811517A2 (pt) * 2007-05-04 2014-11-18 Irm Llc Compostos e composições como inibidores de c-kit e pdgfr cinase.
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
CN103596926B (zh) 2011-12-31 2015-11-25 百济神州有限公司 作为raf激酶抑制剂的稠合三环化合物
TWI876835B (zh) 2015-04-15 2025-03-11 英屬開曼群島商百濟神州有限公司 B-raf激酶抑制劑的馬來酸鹽、其結晶形式及用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101365682A (zh) * 2005-12-08 2009-02-11 千禧药品公司 具有激酶抑制活性的双环化合物
WO2007136572A2 (en) * 2006-05-15 2007-11-29 Merck & Co., Inc. Antidiabetic bicyclic compounds
US20100197924A1 (en) * 2008-12-22 2010-08-05 Millennium Pharmaceuticals, Inc. Preparation of aminotetralin compounds

Also Published As

Publication number Publication date
EP3124472B1 (en) 2018-07-25
EP2797888A4 (en) 2015-09-02
SMT201600302B (it) 2016-11-10
NZ624068A (en) 2016-09-30
ZA201405555B (en) 2015-10-28
PL2797888T3 (pl) 2016-12-30
BR112014013108B1 (pt) 2020-11-24
MX2014007829A (es) 2014-08-01
CA2856347C (en) 2017-05-30
HUE029656T2 (en) 2017-03-28
EA201491305A1 (ru) 2015-04-30
ME02529B (me) 2017-02-20
PT2797888T (pt) 2016-09-09
CY1118226T1 (el) 2017-06-28
WO2013097224A1 (en) 2013-07-04
AU2011384857A1 (en) 2014-05-29
BR112014013108A2 (pt) 2017-06-13
SG11201401725SA (en) 2014-09-26
IL233364A0 (en) 2014-08-31
SI2797888T1 (sl) 2017-01-31
KR20140108541A (ko) 2014-09-11
HRP20160641T1 (hr) 2016-09-23
MX352617B (es) 2017-12-01
EP2797888B1 (en) 2016-06-08
CA2856347A1 (en) 2013-07-04
KR101713391B1 (ko) 2017-03-07
HK1192232A1 (zh) 2014-08-15
AU2011384857B2 (en) 2016-03-03
JP2015506353A (ja) 2015-03-02
ES2588775T3 (es) 2016-11-04
EP3124472A1 (en) 2017-02-01
EA025597B1 (ru) 2017-01-30
DK2797888T3 (en) 2016-09-19
LT2797888T (lt) 2016-10-10
EP2797888A1 (en) 2014-11-05
US9895376B2 (en) 2018-02-20
US20190000857A1 (en) 2019-01-03
HK1221222A1 (zh) 2017-05-26
US20150045355A1 (en) 2015-02-12
IN2014DN06166A (cg-RX-API-DMAC7.html) 2015-08-21
RS55196B1 (sr) 2017-01-31
US9273046B2 (en) 2016-03-01
US20160206621A1 (en) 2016-07-21
IL233364A (en) 2017-06-29
CN103596926A (zh) 2014-02-19
JP5868521B2 (ja) 2016-02-24
US10576087B2 (en) 2020-03-03

Similar Documents

Publication Publication Date Title
CN103596926B (zh) 作为raf激酶抑制剂的稠合三环化合物
JP7207629B2 (ja) Ｒａｆキナーゼおよび／またはＲａｆキナーゼの二量体阻害剤としての縮合三環式ウレア系化合物
EP3280715B1 (en) NOVEL 5 OR 8-SUBSTITUTED IMIDAZO [1, 5-a]PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES
CN103703004B (zh) 作为parp抑制剂的稠合的四环或五环的二氢二氮杂*并咔唑酮
CN102224152B (zh) 吡唑并吡啶pi3k抑制剂化合物及使用方法
CN106083849A (zh) 作为parp抑制剂的稠合的四元或五元环吡啶并酞嗪酮类化合物
WO2014173241A1 (en) Substituted5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones
CN101918403A (zh) 作为酪氨酸激酶抑制剂的吡唑并吡啶类化合物
JP2013503194A (ja) Ｒａｆキナーゼを阻害するための１Ｈ−ピラゾロ［３，４−Ｂ］ピリジン化合物
CN104822658B (zh) 作为多种激酶抑制剂的稠合三环酰胺类化合物
TWI640518B (zh) 作爲ｒａｆ激酶抑制劑的稠合三環化合物
CN105348299B (zh) 作为raf激酶抑制剂的稠合三环化合物
TWI633107B (zh) 作為ｐａｒｐ抑制劑的稠合四或五環二氫二氮呯并咔唑酮
JP6175519B2 (ja) Ｒａｆキナーゼ阻害剤としての縮合三環式化合物
TWI664179B (zh) 經取代之５－（３，５－二甲基異唑－４－基）二氫吲哚－２－酮
JP6541635B2 (ja) Ｐａｒｐ阻害剤としての縮合四環式または縮合五環式ジヒドロジアゼピノカルバゾロン
HK1221222B (en) Fused tricyclic compounds as raf kinase inhibitors
TWI588144B (zh) 作爲ｐａｒｐ抑制劑的稠合四或五環吡啶並酞嗪酮
HK1192232B (en) Fused tricyclic compounds as raf kinase inhibitors
HK1210166A1 (en) Fused tricyclic amide compounds as multiple kinase inhibitors
HK1244787B (zh) 作为吲哚胺、色氨酸二加氧酶抑制剂的5或8-取代的咪唑并[1，5-a]吡啶
HK1210166B (en) Fused tricyclic amide compounds as multiple kinase inhibitors
HK1217485B (zh) 作为raf激酶和/或raf激酶二聚体抑制剂的稠合三环脲类化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1192232

Country of ref document: HK

C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: Fused tricyclic compounds as RAF kinase inhibitors

Effective date of registration: 20160630

Granted publication date: 20151125

Pledgee: Suzhou Industrial Park Biological Industry Development Co.,Ltd.

Pledgor: BEIGENE, Ltd.

Registration number: 2016990000553

PLDC Enforcement, change and cancellation of contracts on pledge of patent right or utility model
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1192232

Country of ref document: HK

PC01 Cancellation of the registration of the contract for pledge of patent right
PC01 Cancellation of the registration of the contract for pledge of patent right

Date of cancellation: 20180423

Granted publication date: 20151125

Pledgee: Suzhou Industrial Park Biological Industry Development Co.,Ltd.

Pledgor: BEIGENE, Ltd.

Registration number: 2016990000553

TR01 Transfer of patent right

Effective date of registration: 20251022

Address after: 215002 Jiangsu Province Suzhou City China (Shanghai) Pilot Free Trade Zone Suzhou Area Suzhou Industrial Park Jinhai Road 29.NO

Patentee after: Baiji Shenzhou (Suzhou) Biotechnology Co.,Ltd.

Country or region after: China

Address before: Greater Cayman, Cayman Islands

Patentee before: BEIGENE, Ltd.

Country or region before: United Kingdom

TR01 Transfer of patent right